Skip to main content
. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464

Table 1.

Infectious Risk Assessment.

Time
Diagnosis Before treatment Anytime
Comprehensive Patient History Anamnesis and comorbidities Inline graphic                  Inline graphic
Past infections/colonization Inline graphic                  Inline graphic
Viral Screening HBV, HCV, and HIV                           Inline graphic
EBV                                 Inline graphic
CMV                                    Inline graphic
Tuberculosis Quantiferon testing or tuberculin skin testing                                   Inline graphic
Immunoglobulin assessment Inline graphic                  Inline graphic

*EBV serology testing is post-screening, triggered by increased transaminases.

**Indicated in high-risk patients receiving ibrutinib and anti-CD20 antibody combination therapy.

***Recommended in high-risk patients.